Archives May 2019

Advanced Therapies Clinical Adoption by Cell and Gene Therapy Catapult

The UK ATTC Network is a world-first system of Advanced Therapy Treatment Centres (ATTCs), operating within the NHS framework and coordinated by CGT Catapult, that is addressing the unique and complex challenges of bringing pioneering advanced therapies to patients. The project has been funded by the Industrial Strategy Challenge Fund, part of the government’s modern Industrial Strategy,

Read More


Dr. Preti Discusses Three-Tier Strategy for Cell Therapy with Global Business Reports

Dr. Robert A. Preti, theCEO and President of Hitachi Chemical Advanced Therapeutics Solutions (HCATS), was recently interviewed by Global Business Reports (GBR) for their 2019 US Biopharmaceuticals report. The GBR report covers a range of topics, such as the state of the biopharma industry, new developments in biopharmaceutical manufacturing, the investment climate for cell and gene

Read More


De-TOXing exhausted T cells may bolster CAR T immunotherapy against solid tumours

A decade ago researchers announced development of a cancer immunotherapy called CAR (for chimeric antigen receptor)-T, in which a patient is re-infused with their own genetically modified T cells equipped to mount a potent anti-tumour attack. Since then CAR T approaches (one of several strategies collectively known as “adoptive T cell transfer”) have made headlines

Read More


Athersys Presents Data From Its Acute Respiratory Distress Syndrome Clinical Trial at American Thoracic Society International Conference

Athersys announced additional favorable data from its exploratory Phase 1/2 acute respiratory distress syndrome (ARDS) clinical trial. Dr. Geoff Bellingan, Medical Director at University College London Hospitals, described the data from the clinical trial, referred to as the MUST-ARDS trial, during his presentation today at the American Thoracic Society International Conference in Dallas, Texas, the

Read More


Santhera Enters into License Agreement with Chiesi Group for Raxone® for the treatment of LHON

Transaction allows Santhera to advance its long-term growth strategy by focusing on the development of its clinical-stage neuromuscular and pulmonary programs Santhera Pharmaceuticals announces that it has entered into an exclusive license agreement with Chiesi Farmaceutici, an international researchfocused healthcare group (Chiesi Group), under which Chiesi Group will in-license Raxone® for the treatment of LHON

Read More


Advanced therapies and carT cells in the next IMI2 calls

Future topics To give potential applicants as much time as possible to form consortia and prepare their proposals, IMI regularly publishes information on possible future topics well in advance of the official Call launch. To ensure you get the latest information on forthcoming Calls, sign up to our newsletter, follow us on Twitter, or join our LinkedIn group.

Read More


Verily Forms Strategic Alliances with Novartis, Otsuka, Pfizer and Sanofi to Transform Clinical Research

Leading biopharmaceutical organizations join Project Baseline initiative to engage more patients and clinicians in research and speed evidence generation Verily, an Alphabet company, today announced strategic alliances with Novartis, Otsuka, Pfizer Inc. and Sanofi to develop digitally innovative, patient-centered clinical research programs using Project Baseline’s evidence generation platform and tools. The Baseline Platform is designed

Read More


ICER Comments on the FDA Approval of Zolgensma for the Treatment of Spinal Muscular Atrophy

In light of additional data from ongoing trials of onasemnogene abeparvovec (Zolgensma®, Novartis/AveXis), as well as the treatment’s final FDA label and just-announced launch price, the Institute for Clinical and Economic Review (ICER) today published an addendum to its Final Evidence Report on treatments for spinal muscular atrophy (SMA). Since the publication of ICER’s Final Evidence Report on

Read More